TITLE

Immunogenicity, Protective Efficacy, and Non-Replicative Status of the HSV-2 Vaccine Candidate HSV529 in Mice and Guinea Pigs

AUTHOR(S)
Bernard, Marie-Clotilde; Barban, Véronique; Pradezynski, Fabrine; de Montfort, Aymeric; Ryall, Robert; Caillet, Catherine; Londono-Hayes, Patricia
PUB. DATE
April 2015
SOURCE
PLoS ONE;Apr2015, Vol. 10 Issue 4, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
HSV-2 vaccine is needed to prevent genital disease, latent infection, and virus transmission. A replication-deficient mutant virus (dl5-29) has demonstrated promising efficacy in animal models of genital herpes. However, the immunogenicity, protective efficacy, and non-replicative status of the highly purified clinical vaccine candidate (HSV529) derived from dl5-29 have not been evaluated. Humoral and cellular immune responses were measured in mice and guinea pigs immunized with HSV529. Protection against acute and recurrent genital herpes, mortality, latent infection, and viral shedding after vaginal HSV-2 infection was determined in mice or in naïve and HSV-1 seropositive guinea pigs. HSV529 replication and pathogenicity were investigated in three sensitive models of virus replication: severe combined immunodeficient (SCID/Beige) mice inoculated by the intramuscular route, suckling mice inoculated by the intracranial route, and vaginally-inoculated guinea pigs. HSV529 immunization induced HSV-2-neutralizing antibody production in mice and guinea pigs. In mice, it induced production of specific HSV-2 antibodies and splenocytes secreting IFNγ or IL-5. Immunization effectively prevented HSV-2 infection in all three animal models by reducing mortality, acute genital disease severity and frequency, and viral shedding. It also reduced ganglionic viral latency and recurrent disease in naïve and HSV-1 seropositive guinea pigs. HSV529 replication/propagation was not detected in the muscles of SCID/Beige mice, in the brains of suckling mice, or in vaginal secretions of inoculated guinea pigs. These results confirm the non-replicative status, as well as its immunogenicity and efficacy in mice and guinea pigs, including HSV-1 seropositive guinea pigs. In mice, HSV529 produced Th1/Th2 characteristic immune response thought to be necessary for an effective vaccine. These results further support the clinical investigation of HSV529 in human subjects as a prophylactic vaccine.
ACCESSION #
102402676

 

Related Articles

  • Oral and Vaginal Tenofovir for Genital Herpes Simplex Virus Type 2 Shedding in Immunocompetent Women: A Double-Blind, Randomized, Cross-over Trial. Bender Ignacio, Rachel A.; Perti, Tara; Magaret, Amalia S.; Rajagopal, Sharanya; Stevens, Claire E.; Meei-Li Huang; Selke, Stacy; Johnston, Christine; Marrazzo, Jeanne; Wald, Anna; Huang, Meei-Li // Journal of Infectious Diseases;12/15/2015, Vol. 212 Issue 12, p1949 

    Background: Tenofovir is a potent anti-human immunodeficiency virus (HIV) agent that decreased risk of herpes simplex virus type 2 (HSV-2) acquisition in HIV pre-exposure prophylaxis trials. Whether tenofovir has utility in established HSV-2 disease is unclear.Methods:...

  • BioVEX Reaches the Clinic with Genital Herpes Vaccine. Moran, Nuala // BioWorld International;8/27/2008, Vol. 13 Issue 35, p3 

    The article reports that BioVEX Inc. has won approval from British regulators for a Phase I study of its genital herpes vaccine that is based on the company's ImmunoVEX live-attenuated vaccine technology. The product has been genetically engineered to prevent it from replicating while having the...

  • Herpes Vaccine Trials Begin. Luntz, Stephen // Australasian Science;Oct2013, Vol. 34 Issue 8, p13 

    The article reports on the progress of phase 1 trials for a vaccine against the herpes simplex virus (HSV-2) virus responsible for genital herpes. An estimated 500 million people have HSV-2 infections. Professor Ian Frazer, who is leading research into the vaccine at the Diamantina Institute,...

  • Vaccination to Reduce Reactivation of Herpes Simplex Virus 2. Cohen, Jeffrey I. // Journal of Infectious Diseases;3/15/2017, Vol. 215 Issue 6, p844 

    The article offers the author's view on the reduction of Herpes Simplex Virus Type 2's (HSV-2) reactivation through vaccination. He mentions the relationship of the disease with genital herpes, encephalitis and transmission of HIV. An overview of virus neutralizing antibody titers in individuals...

  • A Live Attenuated Influenza A(H5N1) Vaccine Induces Long-Term Immunity in the Absence of a Primary Antibody Response. Talaat, Kawsar R.; Luke, Catherine J.; Khurana, Surender; Manischewitz, Jody; King, Lisa R.; McMahon, Bridget A.; Karron, Ruth A.; Lewis, Kristen D. C.; Qin, Jing; Follmann, Dean A.; Golding, Hana; Neuzil, Kathleen M.; Subbarao, Kanta // Journal of Infectious Diseases;Jun2014, Vol. 209 Issue 12, p1860 

    Background. Highly pathogenic avian influenza A(H5N1) causes severe infections in humans. We generated 2 influenza A(H5N1) live attenuated influenza vaccines for pandemic use (pLAIVs), but they failed to elicit a primary immune response. Our objective was to determine whether the vaccines primed...

  • Sanofi Pasteur Partners with Immune Design in Race to Develop First HSV-2 Vaccine. Cartwright, Heather // PharmaDeals Review;2014, Vol. 2014 Issue 11, p55 

    anofi Pasteur and US biotech Immune Design have agreed to pool assets in a collaboration aimed at developing a best-in-class herpes simplex virus-2 (HSV-2) vaccine. The collaboration will evaluate the potential of different combinations of agents, including Sanofi's clinical-stage...

  • Application of a Topical Immune Response Modifier, Resiquimod Gel, to Modify the Recurrence Rate of Recurrent Genital Herpes: A Pilot Study. Spruance, Spotswood L.; Tyring, Stephen K.; Smith, Michael H.; Meng, Tze-Chiang // Journal of Infectious Diseases;7/15/2001, Vol. 184 Issue 2, p196 

    Presents information on a study which investigated the effectiveness of a topical gel formulation of resiquimod in preventing subsequent recurrences of genital herpes. Patient characteristics; Predictors of recurrences; Results and discussion.

  • A sense of immunity: Scientists are detailing the immune system as never before. Keener, Amanda B. // Nature Medicine;Jan2015, Vol. 21 Issue 1, p3 

    The article focuses on the study on responses of immune cell in different human beings by the team of immunologists of the Stanford University's Human Immune Monitoring Center (HIMC), California. Topics discussed include searching new ways for successful immune response and surrogate markers in...

  • INFLUENCE OF IMMUNOMODULATION ON THE FIRST STAGE OF ANTIGEN SPECIFIC RESPONSE TO HERPES VACCINE IN EXPERIMENT. OMAROVA, MARIA; KARALNIK, BORIS; DENISOVA, TATYANA; KALYMBETOV, ALTAI // Medical & Health Science Journal;2011, Vol. 8 Issue 4, p21 

    The influence of immunomodulation on dynamics of early antigen specific response (antigen binding lymphocytes - ABL) was studied in the experiment with rabbits immunization by herpes vaccine. Acceleration of appearance and disappearance of ABL after one-time immunization with herpes vaccine by...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics